Corcept Therapeutics (CORT) to Release Earnings on Thursday

Corcept Therapeutics (NASDAQ:CORT) is projected to post its Q2 2025 quarterly earnings results after the market closes on Thursday, July 31st. Analysts expect Corcept Therapeutics to post earnings of $0.23 per share and revenue of $199.40 million for the quarter. Corcept Therapeutics has set its FY 2025 guidance at EPS.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings data on Monday, May 5th. The biotechnology company reported $0.17 earnings per share for the quarter, hitting the consensus estimate of $0.17. Corcept Therapeutics had a return on equity of 20.40% and a net margin of 19.33%. The business had revenue of $157.21 million during the quarter, compared to analysts’ expectations of $177.93 million. During the same quarter last year, the business posted $0.25 EPS. The business’s revenue was up 7.1% on a year-over-year basis. On average, analysts expect Corcept Therapeutics to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Corcept Therapeutics Stock Performance

NASDAQ CORT opened at $68.20 on Wednesday. Corcept Therapeutics has a fifty-two week low of $32.33 and a fifty-two week high of $117.33. The stock has a 50 day simple moving average of $72.11 and a two-hundred day simple moving average of $68.09. The stock has a market cap of $7.23 billion, a P/E ratio of 58.79 and a beta of 0.15.

Insider Transactions at Corcept Therapeutics

In other news, insider Sean Maduck sold 26,554 shares of the stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $72.23, for a total value of $1,917,995.42. Following the completion of the transaction, the insider owned 85,622 shares of the company’s stock, valued at approximately $6,184,477.06. This represents a 23.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Joseph K. Belanoff sold 40,000 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $82.86, for a total value of $3,314,400.00. Following the completion of the transaction, the chief executive officer directly owned 2,901,985 shares of the company’s stock, valued at $240,458,477.10. This represents a 1.36% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 239,592 shares of company stock worth $18,071,616. 20.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC bought a new position in Corcept Therapeutics during the 1st quarter valued at approximately $518,000. Amundi bought a new position in Corcept Therapeutics during the 1st quarter valued at approximately $450,000. Finally, Royal Bank of Canada increased its position in Corcept Therapeutics by 18.9% during the 1st quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company’s stock valued at $1,757,000 after buying an additional 2,444 shares in the last quarter. Institutional investors own 93.61% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on CORT shares. Canaccord Genuity Group increased their price objective on Corcept Therapeutics from $130.00 to $142.00 and gave the stock a “buy” rating in a report on Tuesday, April 1st. Truist Financial set a $135.00 price objective on Corcept Therapeutics in a report on Tuesday, May 6th. Wall Street Zen cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 14th. HC Wainwright decreased their target price on Corcept Therapeutics from $150.00 to $145.00 and set a “buy” rating for the company in a research report on Tuesday, May 6th. Finally, Piper Sandler increased their target price on Corcept Therapeutics from $128.00 to $131.00 and gave the stock an “overweight” rating in a research report on Thursday, April 3rd. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $138.25.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.